Listed by the USPTO as CHONG, YONG SOO
Tech Center 1600 • Art Units: 1617 1623 1627
This examiner grants 44% of resolved cases
CHONG, YONG SOO works in Tech Center 1600 and Art Unit 1617. The profile reports 892 resolved cases, a 43.8% allowance rate, and a median of 1425 days to allowance. Interview lift is 41.8%, identifying a meaningful positive association between interviews and allowance outcomes despite the lower overall allowance rate in this record.
The leading companies are Schedule 1 Therapeutics Inc., Metabolic Technologies, LLC, and Novartis AG. The principal firms are Dentons Davis Brown PC, GOODWIN PROCTER LLP, and POLSINELLI PC (Main Customer Number). Practitioners may want to emphasize interview preparation and maintain sufficient prosecution runway for a docket with extended median timing.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18566259 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Final Rejection | NOVARTIS PHARMA AG |
| 17760090 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18785196 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18740833 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | Non-Final OA | The Penn State Research Foundation |
| 18835242 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18038821 | SIRTUIN 6 ACTIVATOR | Final Rejection | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION |
| 17916191 | NEW COMPOSITIONS FOR ORAL OR NASAL USE | Final Rejection | md&c Creative Maison SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.8% of resolved applications examined by Yong Soo Chong were allowed (892 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is +41.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Yong Soo Chong took 1,425 days on average from filing to allowance.
Yong Soo Chong examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
